Background {#s1}
==========

As one kind of posttranslational modification, ubiquitination is mediated by a series of enzymatic reactions, mostly initiating protein degradation and thus affecting protein stability ([@B1], [@B2]). Besides, more and more ubiquitination-dependent but protein degradation-irrelevant events are discovered, and further studies indicate that a number of vital cellular processes are triggered by ubiquitination ([@B3], [@B4]). Thus, the ubiquitin system is complex and vast, affecting every aspect of cell life. There are a great many types of ubiquitination, but the dominant forms are monoubiquitination, and Lys48 or Lys63-linked polyubiquitination ([@B5]). The ubiquitin signal is modulated by an enzymatic cascade involving two ubiquitin-activating enzymes (E1), \~40 ubiquitin-binding enzymes (E2), and more than 700 ubiquitin ligases (E3), as well as \~100 of deubiquitinating enzymes (DUBs) ([@B6]--[@B8]). Ubiquitination is a highly conserved and tightly controlled enzymatic process with three joint steps. E1, E2, and E3 work together to form a covalent bond between ubiquitin and its substrate protein for chain editing and precursor processing to complete the processing of ubiquitin, whereas DUBs reverse this progression ([Figure 1](#F1){ref-type="fig"}).

![Key events in ubiquitylation and deubiquitylation. A schematic illustration of three-step enzymatic process in ubiquitination. E1, E2, and E3 form a covalent bond to coordinate the editing between ubiquitin and its substrate protein, while DUBs reverse this processing.](fonc-10-01289-g0001){#F1}

Deubiquitinating enzymes are proteolytic enzymes that can cleave ubiquitin or ubiquitin-like proteins from their target substrate or proproteins, thus inhibiting ubiquitination-mediated protein degradation ([@B9], [@B10]). Based on sequence and domain conservation, six DUB families with distinct structures have been described. Families of cysteine peptidases include ubiquitin-specific proteases (USPs), ubiquitin COOH terminal hydrolases (UCHs), Machado-Josephine domain-containing proteases, ovarian tumor--associated proteases (OTUs), zinc finger--containing ubiquitin peptidases, and motif interacting with ubiquitin-containing novel DUB family (MINDY). In addition, a family of Zn-dependent peptidase JAB1/MPN/MOV34 metalloprotease DUBs (JAMMs, also known as MPN+; 16 members) exists ([@B11], [@B12]). Other protease classes, such as ubiquitin-like proteases, also act as protein-like modifiers, including, but not limited to, SUMO \[Sentrin/SUMO-specific protease (SENP) and de-SUMO-glycosylated isopeptidase (DeSI) family\] and NEDD \[NEDD8-specific protease 1 (NEDP1), member of the SENP family\] ([@B13], [@B14]). For instance, the deISGylating enzyme USP18 is a ubiquitin-like protease that plays a key role in the innate immune system. USP18 acts as an endogenous isopeptidase that cleaves the ubiquitin-like ISG15, which is the representative type I interferon-induced gene and also the first identified ubiquitin-like protease ([@B15], [@B16]).

As mentioned above, multiple modes regulate DUB interaction with ubiquitin and substrate, enabling multiple mechanisms to fine-tune DUB function. The mechanism used by cells to regulate DUB function can be roughly divided into two main types: one is to regulate DUB abundance and position, and the other is to regulate its catalytic activity ([@B17], [@B18]). The catalytic domain of DUBs can directly bind to its substrates and further recognize the specific ubiquitin sites, which determines the activity and specificity of DUBs. All types of DUB classes have at least one ubiquitin binding site, called S1 site, which guides the ubiquitin C-terminus and the frangible bond to the active site, followed by hydrolysis. When double ubiquitin, the distal ubiquitin occupies the S1 site, while the proximal ubiquitin occupies the S1′ site. Moreover, some of DUBs have extra ubiquitin binding sites such as S2, S3, S2′, or S3′, which allow the polymerized ubiquitin chain binding to precise position in enzymes and thus may contribute to the specificity of connection ([@B11], [@B17]).

In addition to conventional effects on the protein stability and expression level, accumulating evidence suggested that the ubiquitin-based regulatory system also plays a crucial role in immunological process. This review hereafter summarizes the novel roles of DUBs and deubiquitination on protein-dependent antitumor immune responses, majorly focusing on different immune cell signaling cascades, including, but not limited to, the tumor necrosis factor (TNF) signaling cascade in T cells and B cells.

Effect of DUBs on Tumoral Immune Checkpoints {#s2}
============================================

Immune checkpoints are part of the immune system. Their role is to prevent a strong immune response and the destruction of healthy human cells by the immune system itself. Immune checkpoints \[including Programmed Cell Death Protein 1 (PD-1) and Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4)\] work when proteins on the surface of immune cells such as T cells recognize and bind to chaperone proteins (such as PD-L1) on other cells, including certain tumor cells. Immune checkpoint blockade--based immunotherapy provides novel and promising approaches for cancer patients, which may result in a long-time control of the tumor or even cure it ([@B19], [@B20]). However, the immune checkpoint inhibitors (such as PD-1/PD-L1 antibody drugs) did not achieve the expected efficacy in the treatment of certain tumors (e.g., pancreatic cancer) ([@B21]). It is well-known that the expression of the target is needed for the corresponding therapy to work. For instance, PD-L1 expression, on tumor cells and/or T cells, is a prognostic factor for PD-1/PD-L1--targeting immunotherapies. Accumulating evidence suggests that the expression of immune checkpoints is regulated at multiple levels from different levels. Recently, increasing evidence indicates that immune checkpoints are also regulated by multiple posttranslational modifications in tumors, thus regulating their ability to mediate immune escape ([@B22]). In this context, DUB has become a crucial factor in ubiquitination and deubiquitination, which is a type of posttranslational modification. Thus, in the first part of our review, we summarize the recent findings regarding the regulatory effects of three key DUBs, USP22, CSN5, and USP9X, on PD-L1, the most representative immune checkpoint ([Figure 2](#F2){ref-type="fig"}).

![Regulation of PD-L1 by DUBs. A schematic illustration of multiple DUBs involved in PD-L1 deubiquitylation, including USP22, CSN5, and USP9X. ICD, intracellular domain; TM, transmembrane domain; EC, extracellular domain; SIG, signal sequence.](fonc-10-01289-g0002){#F2}

USP22
-----

USP22 is a novel human DUB composed of 525 amino acids, and containing Cys, Asp, His, and Asp/Asn, which are highly conserved domains of the UBP family in DUBs ([@B23]). Some results show that USP22 is overexpressed in many tumor types and affects tumorigenesis and development by affecting cell cycle ([@B24]--[@B28]). However, our previous study demonstrated that USP22 induces the deubiquitination of PD-L1 and prevents PD-L1 degradation. Binding directly to the C-terminal cytoplasmic tail and transmembrane region of PD-L1, USP22 catalyzes the deubiquitination of PD-L1 and stabilizes PD-L1 in a CDK4-independent manner ([@B29]). Hepatocellular carcinoma is the tumor that better fits in the exploration of tumor inhibition mediated by USP22--PD-L1, because the expression of USP22 in this tumor is higher than its expression in other cancer types ([@B30]). In pancreatic cancer, in addition to affecting tumor progression through the regulation of the cell cycle, USP22 can also influence tumorigenesis and development by regulating immune cell infiltration through nuclear functions independent of its effects on PD-L1 protein stability ([@B31]). Although the expression of PD-L1 is a predictive biomarker for the result of immunotherapy in patients with multiple tumor types, the therapeutic effect of targeting PD-L1 is unsatisfactory ([@B21], [@B32], [@B33]). Our hypothesis is that the poor clinical efficacy of the treatments targeting PD-L1 may be due to the stabilization of PD-L1 mediated by USP22, abolishing the effect of anti--PD-L1 drugs ([@B30]). Therefore, a targeted inhibition of USP22-mediated deubiquitination of PD-L1 can be a new potentially effective immunotherapeutic strategy.

CSN5
----

COP9 signalosome subunit 5 (CSN5), which is also called JAB1, is the fifth component of the CSN regulatory complex and contains an evolutionarily conservative Jab1/Mpr1p and Pad1pN terminus (MPN) domain metalloenzyme (JAMM) motif interface with the ubiquitin--proteasome pathway. CSN5 plays critical roles in regulating the invasion and migration of cancer cells, as well as exosome protein sorting ([@B34]--[@B37]). Some results by mass spectrometry analysis revealed that CSN complex is the interaction partner of PD-L1 ([@B34], [@B38], [@B39]). Acting as a DUB, CSN5 inhibits the ubiquitination processing and subsequent proteasomal degradation of PD-L1 and thus stabilizing its protein expression in cancer cells. Tumor necrosis factor α stimulation activates nuclear factor κB (NF-κB), which induces CSN5 expression, resulting in PD-L1 stabilization. However, the CSN5 inhibitor curcumin inhibits the stability of PD-L1, making cancer cells sensible to an anti-CTLA4 therapy ([@B38]). In colorectal cancer, Liu et al. ([@B39]) suggested that the C-C motif chemokine ligand 5 (CCL5), secreted from macrophages, inhibits T cell--mediated killing in HT29 cells. Mechanistically, CCL5 promotes the immune escape through causing the formation of STAT3/NF-κB p65 complex, which bound to the *CSN5* promoter, and in turn modulates the deubiquitination and stability of PD-L1 *in vitro* and *in vivo* ([@B39]).

USP9X
-----

Previous studies showed that the function of USP9X in regulating cancer cells is complex and diverse. Through a ubiquitin-specific protease activity, USP9X not only plays a paramount role in regulating the proliferation, apoptosis, and adhesion of cancer cells ([@B40], [@B41]), but also maintains the stability of DNA replication-fork and DNA-damage checkpoint responses, thus affecting radiosensitivity ([@B42], [@B43]). Recently, it has been revealed that USP9X also plays a vital role in regulating immune checkpoints. Indeed, USP9X induces PD-L1 deubiquitination and regulates its stabilization by ubiquitin specific protease activity ([@B44]). In Oral Squamous Cell Carcinoma (OSCC) cells, the high expression of USP9X increases the deubiquitination of PD-L1 and reduces its degradation, resulting in protein accumulation in these cells ([@B44]). Thus, targeting PD-L1 by blocking USP9X may be a potentially useful strategy in the treatment of cancer cells.

Role of DUBs in T Cell Function and Immune Response {#s3}
===================================================

Ubiquitination is one kind of critical mechanism in regulating the immune response and T-cell function. Although the full-scale roles of DUB in immunity have not been thoroughly understood, significant progresses have recently been reported by some studies regarding immunoregulation by DUBs. In the following part, we discuss the up-to-date findings on the molecular features and signaling function of deubiquitylation in immune response and T-cell function ([Table 1](#T1){ref-type="table"}). There are many DUBs regulating the immune response, majorly from USP family, including CYLD, USP4, USP7, USP8, USP9X, USP11 USP15, USP17, USP18, USP25, and USP47, as well as OTU family, including A20, deubiquitylating enzyme A (DUBA), Otud7b, OTULIN, BRCC/ABRO, and Zranb1. Specifically, USP11, A20, and OUTLIN contribute to immune response through NF-κB pathway, whereas USP25 regulates innate immunity by deubiquitylation of the adaptor protein TRAF3 ([@B45]--[@B49]). Moreover, USP7, USP47, and BRCC3/ABRO can activate the NLRP3 inflammasome ([@B50]--[@B54]). Furthermore, USP4, USP15, USP17, and USP18 control T~H~17 differentiation through RORγt pathway. Additionally, USP18 is a key regulator of interferon signaling and its mediated innate immune response ([@B45], [@B55]--[@B58]). Because the regulatory mechanism of DUBs in immunity is quite complex, we focus on the representative ones in this part.

###### 

Deubiquitinases involved in immune response and T-cell regulation.

  **Family**   **DUB**      **Function**                                                                                                **Target**
  ------------ ------------ ----------------------------------------------------------------------------------------------------------- --------------------
  USP          CYLD         Survival of immature NKT cells                                                                              IKK
                            T cell activation                                                                                           TAK1/IKK
                            Thymocyte development                                                                                       LCK
                            Treg development                                                                                            IKK/Smad7
               USP4         T~H~17 differentiation                                                                                      RORγt
               USP7         Treg function                                                                                               Foxp3/ Tip60
                            inflammasome activation                                                                                     NLRP3
               USP8         Thymocyte maturation                                                                                        CHMP5
               USP9X        TCR signaling and central tolerance                                                                         Bcl10/Zap70/Themis
               USP10        Unknown                                                                                                     T-bet
               USP11        Immune response                                                                                             NF-κB pathway
               USP15        T-cell activation and differentiation                                                                       MDM2
                            T~H~17 differentiation                                                                                      RORγt
               USP17        T~H~17 differentiation                                                                                      RORγt
               USP18        T~H~17 differentiation                                                                                      RORγt
                            Innate immune response                                                                                      IFN-γ pathway
               USP25        Innate immune response                                                                                      TLR pathway
               USP47        Inflammasome activation                                                                                     NLRP3
  OTU          A20          NKT cell differentiation                                                                                    MALT1
                            CD4 T-cell survival                                                                                         RIPK3
                            T-cell survival                                                                                             mRORC1
                            CD8 T-cell activation/Treg development/cell-extrinsic regulation of T~H~1 and T~H~17 cell differentiation   NF-κB pathway
               DUBA         T-cell activation and differentiation                                                                       UBR5
               Otud7b       T~H~17 differentiation                                                                                      Zap70
               OTULIN       Innate immune response                                                                                      NF-κB pathway
               BRCC3/ABRO   Inflammasome activation                                                                                     NLRP3
               Zranb1       Cell-extrinsic regulation of T~H~1 and T~H~17 cell differentiation                                          Jmjd2b

A20
---

A20, also known as TNFAIP3, is a zinc finger domain--containing deubiquitinase that limits the function of TNF receptor (TNFR) and induces NF-κB activation via innate immune receptors, such as Toll-like receptors (TLRs) and NOD2 (nucleotide-binding oligomerization domain protein 2, an intracellular pattern recognition molecule) ([@B59]--[@B62]). A unique feature of A20 is not only its capability to act as a DUB, but also works as an E3 ligase ([@B59]). The amino-terminal (N-terminal) region of A20 contains an OUT (the ovarian tumor--related proteases) domain, which is composed of \~24 members in the human genome and forms the second largest DUB family in mammalian. A20 has DUB activity toward several NF-κB signaling factors that regulate both innate and adaptive immune responses. In addition, A20 inhibits receptor-interacting protein kinase 1 (RIP1, also called RIPK1) K63-linked polyubiquitination to block NF-κB signaling downstream of TNFR1 ([@B59], [@B62], [@B63]). Of note, the carboxy-terminal domain of A20 contains seven C2/C2 zinc finger domains; thus, it is able to act as an E3 ubiquitin ligase. For instance, A20 can polyubiquitinate RIP with K48-linked ubiquitin chains, thereby promoting the proteasomal degradation of RIP ([@B59]).

In addition to the TNFR pathway, the function of A20 has been described in the IL-1R/TLR4 pathway. A20 targets E3 ligases via being recruited to the E3 ligases TRAF2, TRAF6, and cIAP1/2, disrupting the connection between E2 and E3 ubiquitin enzyme complex, and destroying the interactions with the E2 enzymes Ubc13 and UbcH5c. The ubiquitination and degradation of the E2 enzymes occur at later time points after stimulation ([@B64]). A20 was the first DUB found to have a role in innate immune regulation. Some studies have shown that the loss of A20 leads to continued activation of NF-κB by TLRs and TNFR by breaking the tolerance of the innate immune system to the commensal intestinal microflora, causing abnormal homeostatic TLR signaling and the production of pro-inflammatory mediators ([@B60], [@B62], [@B65]). Therefore, A20 is a key protein that regulates immune homeostasis and TLR signaling *in vivo*. In different immune tissues, the important role of A20 has been described using A20 conditional knockout mice. The deficiency of A20 in B cells makes them hyperresponsive after an appropriate activation stimuli, and this phenomenon leads to a higher NF-κB activation, as well as an enhanced proliferation and survival ([@B66]). Recent results revealed that the level of pro-inflammatory cytokines including IL-6 increases in *Tnfaip3fl/fl CD19-Cre* mice. Interleukin 6 causes an expansion of myeloid and effector T cells as well as a loss of B-cell tolerance ([@B66], [@B67]). The reason may be due to the fact that the deficiency of A20 results in the accumulation of K63-linked ubiquitination by TRAF6 and RIP stimulation, causing prolonged activation of NF-κB signaling pathway and abnormal expression of pro-inflammatory cytokines. A20 also induces RIP2 deubiquitylation, thereby negatively regulating NF-κB activation and inducing the production of pro-inflammatory cytokines by the intracellular PRR and NOD2. Thus, A20 plays a crucial role in B-cell homeostasis and the control of inflammatory responses.

In T-cell development, T lymphocytes express high levels of A20, which decrease after T-cell activation. A great amount of evidence is available regarding the effect of A20 on natural killer T (NKT) cell development. Although A20 is not necessary for the survival of immature NKT cells, it is an important regulator in mediating their maturation. According to the secretion of cytokines, NKT cells are classified into three subgroups, such as NKT1, NKT2, and NKT17, which are characterized by the production of IL-4, IL-17, and interferon γ (IFN-γ). The loss of A20 in T cells can greatly reduce the number of mature NKT cells, but does not affect the early stages of immature NKT cells. In other words, the loss of A20 reduces the quantity of NKT1 and NKT2 cells, without affecting NKT17 cells in organs and the peripheral blood ([@B68], [@B69]).

A20 plays a vital role in mediating CD8 T-cell response, which involves the inhibition of NF-κB signaling pathway. A20 deficiency in mature T cells can lead to excessive production of IL-2 and IFN-γ in CD8^+^ T cells by increasing NF-κB activation. High expression of A20 in tumor-infiltrating CD8^+^ T cells has been reported to be related to poor antitumor immune response, and the loss of A20 is associated with the increased ability of CD8^+^ T cells in tumor clearance. However, another study suggested that the function of A20 in regulating T cells is quite complex, because it could regulate primary and memory responses of CD8^+^ T cells in opposite manners ([@B70], [@B71]). A20 also shows vital influence on the survival of activated CD4^+^ T cells, involving the K5 ubiquitination of RIPK3, which induces the formation of the RIPK1--RIPK3 complex required to induce necrotic cell death. Therefore, A20 deficiency is important for the ubiquitination of RIPK3 and the formation of the RIPK1--RIPK3 complex, which exacerbates the death of CD4^+^ T cells ([@B72]). Additionally, A20 mediated CD4^+^ T-cell survival through promoting autophagy, which is caused by the inactivation of mTOR complex 1 (mTORC1), a major inhibitor of autophagy ([@B73], [@B74]).

As regards T-cell tolerance, the regulating mechanism involves inability to induce and regulatory T cell (Treg)--mediated suppression of autoreactive T cells, which were eliminated during central tolerance ([@B75], [@B76]). A20 plays a negative regulatory role in thymus development of Tregs by inhibiting RelA (a classic member of NF-κB). The specific loss of A20 in T cells is related to the increase of Tregs in the thymus tissue and surrounding lymphoid organs. Nevertheless, the unusual thing is that A20 deficiency has no effect on the survival or proliferation of Tregs, which seems to reduce the dependence of thymic Treg precursor cells on IL-2 during development *in vivo* ([@B77]).

CYLD
----

CYLD was initially identified as a tumor suppressor, and its mutation leads to familial cylindromatosis. The mutation often occurs in the carboxy-terminal (C-terminal) portion of CYLD, which contains a DUB domain 10, interacts with NEMO, and has deubiquitinating activity ([@B78], [@B79]). It is now evident as demonstrated by functional proteomics that CYLD is a member of the USP family of DUBs that negatively regulates NF-κB activation by binding to multiple signaling molecules including NF-κB essential modulator, two IKK regulatory proteins (members of the TRAF family), the NF-κB coactivator BCL-3, the IKK \[inhibitor of NF-κB (IκB) kinase\], the steroid receptor coactivator (SRC) protein tyrosine kinase LCK, RIP1, and TRPA1 (transient receptor potential channel A1) ([@B79]--[@B87]).

Recent evidence suggests that CYLD is a protein specifically linked to K63, which facilitates the interaction of CYLD targets in the recruitment and activation of downstream signaling molecules ([@B88], [@B89]). Because of the unique structure of the USP catalytic domain, CYLD has specific determinants that can mediate the uncoupling of K63-linked ubiquitin chains. However, it does not mean that CYLD is precisely a K63-specific DUB, because there is evidence from two studies indicating that CYLD has activity to prevent the proteasomal degradation of some target proteins by targeting toward K48-linked ubiquitin chains ([@B82], [@B85], [@B90]--[@B92]). Moreover, adaptor proteins may be involved in the function of CYLD. For instance, p62, one adaptor protein, can promote the deubiquitylation of TRAF6 (one of p62 targets) by CYLD. Moreover, p62 is able to regulate the DUB activity of CYLD through induction of its ubiquitylation ([@B84], [@B93]).

An important function of CYLD is to regulate the immune response. CYLD deficiency leads to spontaneous B-cell activation and proliferation ([@B94]). As regards the regulation of the innate immunity, CYLD activates the nuclear factor of *Streptococcus pneumoniae*--activated T cells by deubiquitinating the upstream kinase TAK1, thus inducing its inhibition ([@B95]).

The first DUB shown to regulate thymocyte development is CYLD. The role of CYLD in the regulation of thymocyte development involves IKK activation ([@B96]). Moreover, defined by the expression of T4 coreceptors CD4 and CD8, T-cell development in the thymus is divided into three different stages: double-negative, double-positive (DP), and single-positive (SP) cells. The loss of CYLD attenuates thymocyte development because it affects the DP to SP stages, leading to a reduced quantity of T cells in the peripheral lymphoid organs. In regulating T-cell receptor (TCR) signaling during the transition from DP thymocytes to mature SP thymocytes, CYLD targets the tyrosine kinase LCK, playing a critical role in this transition ([@B85]). In addition, CYLD regulates the differentiation of myeloid thymocytes required for the negative selection of thymocytes ([@B97]). In contrast to A20, CYLD also has an important role in regulating NKT-cell development. CYLD is not only essential for the maturation of NKT cell, but also for the survival of immature NKT cells. Because of abnormal activation of NF-κB, CYLD deficiency attenuates the signal transduction of NKT cells stimulated by IL-7 ([@B98]).

In the activation and survival of T cells, CYLD can regulate the dynamic ubiquitination of TAK1 and thus controls TCR/CD28 stimulation in T cells under homeostatic conditions. CYLD deficiency results in the hyperactivation of IKK, JNK, and the downstream transcription factor NF-κB by hyperubiquitination and activation of TAK1 ([@B86]). Therefore, CYLD plays an important negative regulator role in TCR activation and homeostasis. Like A20, CYLD negatively regulates the Treg development; thus, CYLD deficiency increases the frequency of Treg in the thymus tissue and peripheral lymphoid organs ([@B99]). Because NF-κB is an important inducer in Treg development, CYLD mainly regulates Treg development by inhibiting the NF-κB pathway. Furthermore, CYLD can regulate the development of Treg by inhibiting TGFβ signaling that in turn deubiquitinates smad7 ([@B100], [@B101]). An evidence showed that although CYLD inhibits the development of Tregs, it is regulating the immune suppressive function of Tregs, because enhanced Treg production was observed in mice expressing the CYLD (ex7/8), a non-functional CYLD splice variant ([@B102]).

USP15
-----

In marked contrast with CYLD and A20, USP15 negatively regulates K48-linked ubiquitination of IκBα, which triggers IκBα proteolysis and the nuclear translocation of NF-κB, as well as downstream signaling pathways ([@B103]). Recent studies showed that the NFAT signaling is also regulated by USP15 ubiquitin. First, USP15 interacts with MDM2, inhibits ubiquitination, and stabilizes MDM2, an important E3 ligase that mediates the ubiquitination and proteolysis of NFATc2 members of the NFAT family and negatively regulates TCR signals. Subsequently, the activated NFATc2 is conjugated to the K48 ubiquitin chain through the E3 ubiquitin ligase MDM2, inducing its proteasome degradation ([@B56]). Because of the ubiquitin-dependent degradation, together with TCR/CD28 stimulation, MDM2 can be transiently down-regulated, and the loss of USP15 greatly promotes the degradation of MDM2 in T cells ([@B56]). Therefore, USP15 is deemed as an essential adaptor protein for MDM2-mediated NFAT ubiquitination and T-cell activation.

In T-cell differentiation, USP15 regulates IFN-γ production in activated CD4^+^ T cells at early stage. The main feature of T~H~1 cells is the production of cytokine IFN-γ, as well as the participation in the immune responses against intracellular pathogens ([@B56], [@B104]). The lack of USP15 makes CD4^+^ naive T cells highly responsive to IFN-γ produced by TCR/CD28 stimulation, thus leading to promoted T~H~1 differentiation *in vitro* under the stimulation of a suboptimal dose of T~H~1 polarized cytokine IL-12. In addition, USP15 deficiency in a mouse tumorigenic model enhanced T~H~1 response *in vivo* ([@B56]). As mentioned previously, USP15 is not only the DUB of MDM2, but also mediates the ubiquitination of K48 and the degradation of activated NFATc2. NFATc2 is a transcription factor that is critically related to the induction of IFN-γ ([@B56]). Some studies show that USP15 is involved in the differentiation of T~H~17 cells. USP15 targets RORγt (T~H~17 lineage transcription factor) for deubiquitylation, but it regulates function rather than the stability of RORγt. The mechanism of action is the following: USP15 increases the association between RORγt and SRC1 by removing ubiquitin from lysine 446 of RORγt, thereby facilitating the transactivation function of RORγt and T~H~17 differentiation ([@B105]).

DUBA
----

The DUBA is an OTU family member (also called OTUD5), which was found acting as a negative regulator of type I IFN production through siRNA screening ([@B106]). Like A20, DUBA has an OTU domain and can selectively cleave K63-linked ubiquitin chains in transfected cells. However, unlike A20 and CYLD, DUBA is not necessary for the negative regulation of NF-κB, because knockdown of DUBA via its targeted specific siRNA shows almost negligible effects on the activation of NF-κB is ([@B106]). In contrast, DUBA selectively regulates the activation of IFN-regulatory factor 3 (IRF3) and IRF7, both regulating IFN expression. DUBA not only interacts with TRAF3 and inhibits TRAF3 ubiquitination, but also interrupts the interaction between TRAF3 and TBK1. Therefore, our hypothesis is that the K63-linked ubiquitin chain of TRAF3 may promote its interaction with the TBK1--IKKε complex ([@B107], [@B108]).

Deubiquitylating enzyme A is another T~H~17 regulator. On the one hand, DUBA deletion in T cells promotes the production of T~H~17 cells. On the other hand, DUBA-deficient Tregs, which still have immunosuppressive functions *in vitro* and *in vivo*, can produce IL-17A under TCR stimulation ([@B109]). The mechanism involved is that DUBA stabilizes UBR5, which is an E3 ubiquitin ligase that mediates the ubiquitination and proteasomal degradation of RORγt of the T~H~17 lineage. Therefore, DUBA or UBR5 knockout can enhance the level of RORγt and promote T~H~17 cell differentiation ([@B109]).

USP9X
-----

Unlike the several DUBs mentioned previously, which can negatively regulate TCR-stimulated NF-κB signaling, USP9X regulates TCR-proximal signaling and T-cell activation. USP9X binds to Bcl10 and inhibits its ubiquitination under TCR stimulation by deleting the K48-linked ubiquitin chain from Bcl10 ([@B110]). A recent study suggests that although USP9X exerts a positive role in TCR signaling, T cell--specific USP9X-deficient mice still have a large number of antigen-stimulated T cells, as well as expanded PD-1-- and OX40-expressing populations, which is actually consistent with immune hyperactivity, thus developing a lupus-like autoimmune disease. This effect may be due to a defect in the negative selection of thymocytes in USP9X-deficient mice and consequent generation of self-reactive T cells ([@B111], [@B112]). USP9X also uncouples K48-linked polyubiquitin chains from Themis, a TCR proximal signal molecule that regulates thymocyte development ([@B111]). These findings highlight the critical role of USP9X in regulating TCR signaling in thymocytes and peripheral T cells, which also indicates multiple targets are involved in such regulation.

Perspective
-----------

In addition to the well-established classical functions, DUBs also play crucial roles in the immunological regulation of tumors. In a deubiquitination-dependent manner, DUBs not only can stabilize the key immunosuppressive checkpoint PD-L1 to cause the enhancement of tumor-immune escape, but also can directly affect T-cell activation and consequent antitumor immune response by exerting an action on the critical regulators of T-cell activity. Deubiquitinating enzymes act as secondary checkpoints to determine the efficacy of current tumor immunotherapies at the level of posttranslational modification.

Nowadays, small molecule inhibitors targeting DUBs are constantly being developed ([Table 2](#T2){ref-type="table"}). For instance, WP1130 is designed as a relatively broad range inhibitor to block the activity of USP5, USP9X, USP14, and UCH37. In addition, VLX1570, a USP14 and UCHL5 inhibitor, has entered the first phase of clinical trials of multiple myeloma (NCT02372240). Considered the predominance of immune checkpoint blockade in immunotherapy, as well as the mainstream status of immunotherapy in cancer therapy, DUBs-targeting strategy will have a great translational potential and application prospect in the future cancer immunotherapy. Therefore, it is urgent to further identify the core DUBs in tumor immune regulation and clarify the target and mechanism of its action in depth.

###### 

Deubiquitinating enzyme--targeted drug candidates.

  **Name**                                               **Target(s)**                                                                                                                                                     **Efficacy**                   **References**
  ------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------ --------------------
  PR-619                                                 ATXN3, BAP1, JOSD2, OTUD5, UCH-L1, UCH-L3, UCH-L5/UCH37, USP1, 2, 4, 5, 7, 8, 9X, 10, 14, 15, 16, 19, 20, 22, 24, 28, 47, 48, VCIP135, YOD1, PLpro, DEN1, SENP6   EC50: 1--20 μM                 ([@B113])
  P5091 (P005091)                                        USP7, 47                                                                                                                                                          EC50: 4.2 μM, 4.3 μM           ([@B114], [@B115])
  P22077                                                 USP7, 47                                                                                                                                                          EC50: 8 μM                     ([@B113], [@B116])
  HBX41108                                               USP7                                                                                                                                                              IC50: 0.27 μM                  ([@B117])
  HBX19818                                               USP7                                                                                                                                                              IC50: 28.1 μM                  ([@B118])
  HBX28258                                               USP7                                                                                                                                                              IC50: 22.6 μM                  ([@B118])
  9-oxo-9H-indeno \[1,2-b\]pyrazine-2,3-dicarbonitrile   USP7, USP8                                                                                                                                                        IC50: 3.5 μM, 0.29 μM          ([@B119])
  b-AP15                                                 UCHL5                                                                                                                                                             IC50: 2.1 μM                   ([@B120])
  VLX1570                                                USP14, UCHL5                                                                                                                                                      EC50: 29 nM                    ([@B121])
  Degrasyn (WP1130)                                      USP5, USP9X, USP14, UCH37                                                                                                                                         IC50: 1-5 μM                   ([@B122], [@B123])
  IU1                                                    USP14                                                                                                                                                             IC50: 4.7 μM                   ([@B124])
  pimozide                                               USP1/UAF1                                                                                                                                                         IC50: 2 μM                     ([@B125])
  GW7647                                                 USP1/UAF1                                                                                                                                                         IC50: 5 μM                     ([@B125])
  Isatin O-acyl oxime derivatives (30, 50, 51)           UCHL1, UCHL3                                                                                                                                                      IC50: 0.80-0.94 μM, 17-25 μM   ([@B126])
  AZ1                                                    USP25, USP28                                                                                                                                                      IC50: 0.62 μM, 0.7 μM          ([@B127])
  ML364                                                  USP2, USP8                                                                                                                                                        IC50: 1.1 μM, 0.95 μM          ([@B128])
  ML323                                                  USP1-UAF1                                                                                                                                                         IC50: 76 nM                    ([@B129])
  TCID                                                   UCH-L3                                                                                                                                                            IC50: 0.6 μM                   ([@B126])
  Vialinin A                                             USP4, USP5                                                                                                                                                        IC50: 1--25 μM                 ([@B130])
  XL188                                                  USP7                                                                                                                                                              IC50: 90--190 nM               ([@B131])
  Chalcone derivatives (AM146, RA-9, RA-14)              DUB                                                                                                                                                               IC50: 1-13 μM                  ([@B132])
  GRL0617                                                PLpro                                                                                                                                                             EC50: 10--15 μM                ([@B133])
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DUB

:   deubiquitinating enzyme

E1

:   ubiquitin-activating enzyme

E2

:   ubiquitin-binding enzyme

E3

:   ubiquitin ligase

USP

:   ubiquitin-specific protease

UCH

:   ubiquitin COOH terminal hydrolase

MJD

:   Machado-Josephine-containing protease

OUT

:   ovarian tumor protease

MINDY

:   motif that interacts with the novel DUB family containing ubiquitin

JAMM

:   JAB1/MPN/MOV34 metalloprotease DUB

SENP

:   Sentrin/ SUMO-specific protease

DeSI

:   de-SUMO-glycosylated isopeptidase

NEDP1

:   NEDD8-specific protease 1

PTM

:   posttranslational modification

HCC

:   hepatocellular carcinoma

CSN5

:   COP9 signalosome 5

JAMM

:   JAB1/MPN/Mov34 metalloenzyme

CCL5

:   C-C motif chemokine ligand 5

TNF

:   tumor necrosis factor

TNFR

:   TNF receptor

TLR

:   Toll-like receptor

NOD2

:   nucleotide-binding oligomerization domain protein 2

N-terminus

:   amino-terminus

OUT

:   ovarian tumor--related proteases

RIPK3

:   receptor-interacting protein 3

mTORC1

:   mTOR complex 1

IκB

:   inhibitor of NF-κB

IKK

:   IκB kinase

TRPA1

:   transient receptor potential channel A1

DN

:   double negative

DP

:   double positive

SP

:   single positive

mTEC

:   myeloid thymocyte

NKT

:   natural killer T

SRC1

:   steroid receptor coactivator 1

DUBA

:   deubiquitylating enzyme A

IFN

:   interferon

IRF3

:   IFN-regulatory factor 3.
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